Stanford researchers at the Xing Lab have developed a novel technique to enable retrospective tuning of soft tissue contrast in MRI (i.e. adjusting the contrast after the image acquisition) using a deep learning-based strategy.
Researchers at Stanford have developed humanized therapeutic antibodies to treat cancers, particularly melanoma, inflammatory disorders such as sarcoidosis and skin and organ fibrosis.
An interdisciplinary team of Stanford engineers have developed a low-cost, patented, in situ method to efficiently produce electricity from organic matter such as wastewater.
Stanford researchers have developed a new method and medical device to close the abdominal wall fascia after laparotomy to reduce the incidence of incisional hernias. Incisional hernias occur in nearly 50% of high risk patients leading to costs of about $3B annually.
Stanford researchers have discovered that dietary metabolites, specifically alpha-ketoglutarate, are able to delay retinal degeneration to treat blinding retinal diseases regardless of the type of retinal condition.
Stanford researchers have developed a hydrodynamic treadmill system for a tracking microscope that allows long term observations of biological and abiotic systems over large length and time scales.
Stanford researchers have designed a high-voltage cascode GaN/SiC device combining the advantages of both a GaN and an SiC device (i.e. reduced gate loss/simple gate drive requirements)
Researchers at Stanford are advancing a new treatment for heart failure based on the transfer of mitochondria-rich extracellular vesicles from iPSC-derived cardiomyocytes. Heart failure is the leading cause of hospital admission in the U.S.
Researchers at Stanford have developed the first polygenic risk model of its kind for estimating personalized genetic risk profiles. No other genetic model is able to identify biological drivers of disease risk and generate disease subtypes.